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tumor. Attempts of developing tumor targeting drug, which 
would be capable to deliver necessary amount of high atomic 
number element into the tumor haven’t succeed yet. Another 
possible way to deliver such elements into the tumor is to 
utilize some pathological processes caused by tumorogenesis 
such as blood barrier disruption in case of brain tumors or 
high vascularization inherent to some tumors. In this work 
the efficacy of x-rays irradiation with disodium 
gadopentetate (Gd-DTPA) administration in treating highly 
vascularized transplanted tumor in mice was studied. 
 
Material and Methods: C57Bl/6 mice with transplanted 
adencarcinoma Ca755 were used in the study. Animals were 
divided into three groups. 1st group undergo no treatment. 
2nd group was irradiated with 10 Gy of x-rays. Animals in 3rd 
group were administered with 0.3 ml of 0.5M water solution 
of Gd-DTPA, containing 23 mg of gadolinium and then 
irradiated as well. Administration of Gd-DTPA was performed 
with single systemic injection. Irradiation was performed 
using x-rays generator with anode voltage of 200 kV. 
Antineoplastic efficacy was estimated by measuring tumor 
volume and life span of mice. 
 
Results: Tumor growth rate plots are presented in Figure. 
 
Tumor growth delay for test group was 13 days whereas in 
irradiated control group tumor growth delay was just 4 days. 
Median life span was 22 days, 37 days and 46 days for control 
group, irradiated control group and test group respectively. 
In test group 25% of animals have full tumor regression 
whereas in both control groups no tumor regression was 
observed. Endpoints of antitumor evaluation, i.e. T/C% ratio 




Conclusion: Obtained results show that systemic injection of 
extracellular drug with gadolinium prior irradiation with x-
rays provide enough amount of gadolinium in highly 
vascularized tumors and lead to significant increase of 
antineoplastic efficacy of x-rays irradiation. 
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Purpose or Objective: With the development of molecular 
biology and gene engineering，more and more attention has 
been paid to gene-radiotherapy of malignant tumors. The 
combination of gene therapy and radiotherapy is regarded as 
one of the effective methods for the treatment of tumors. 
This research focused on the Egr-1 promoter with radiation-
induced effect, p53 and endostatin genes with function of 
inducing apoptosis and anti-angiogenesis, and EGFR-targeted 
adenovirus vector with higher cell infection efficiency. The 
therapeutic effect of adenovirus vectors Ad.Egr-wtp53-
endostatin and Ad.CMV-sCAR-EGF combined with 
radiotherapy in non-small cell lung cancer is here reported.  
 
Material and Methods: The adenovirus vectors Ad.Egr-wtp53-
endostatin containing both wild type p53 and antiangiogenic 
molecule endostatin genes downstream of early growth 
response-1 (Egr-1) and Ad.CMV-sCAR-EGF containing 
coxsackie virus receptor extracellular segment (sCAR) and 
epidermal growth factor (EGF) were constructed using gene 
recombination technique. The infection efficiency in non-
small cell lung cancer cell lines (A549, LK-2 and Lu65) of 
Ad.Egr-wtp53-endostatin mediated with Ad.CMV-sCAR-EGF 
expressed fusion protein sCAR-EGF was detected. The 
expression of wild type p53 and endostatin genes by the 
radiation-sensitive promoter Egr-1 in non-small cell lung 
cancer cell lines were observed. Immunodeficient mice 
(NOD/scid) subcutaneously implanted with A549 cells were 
treated by conventional radiotherapy (2Gy×6) and/or gene 
therapy (intratumor injection of adenovirus vectors Ad.Egr-
wtp53-endostatin and Ad.CMV-sCAR-EGF 24 h before the first 
and fourth local doses). Immunologic mechanisms were 
explored. 
 
Results: The fusion protein SCAR-EGF expressed from 
Ad.CMV-sCAR-EGF significantly increased infection efficiency 
of Ad.Egr-wtp53-endostatin in human non-small cell lung 
cancer cell lines. Cancer control was most significantly 
improved in the group receiving local radiotherapy combined 
with gene therapy as shown by prolongation of mean survival 
time by 75.2%, reduction in average tumor weight by 88.7%, 
decrease in pulmonary metastasis by 76.9% and decrease in 
intratumor angiogenesis by 80.4% as compared to local 
radiotherapy alone (P < 0.05). Immunologic studies showed 
stimulated natural killer (NK) and cytotoxic T lymphocyte 
(CTL) activity as well as increased interferon-γ (IFN- γ) and 
tumor necrosis factor-α (TNF-α) secretion in this combined 
treatment group as compared with the group receiving local 
treatment alone (P < 0.05). 
 
Conclusion: The experimental findings in the present study 
showed that adenovirus vectors Ad.Egr-wtp53-endostatin and 
Ad.CMV-sCAR-EGF in combination with local radiotherapy 
could improve the tumor control. These observations may set 
the stage for developing clinical protocols with recombinant 
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Purpose or Objective: One of the main effects of 
radiotherapy is the generation of free radicals as a 
consequence of the incidence of radiation on the aqueous 
molecules present in the cells. The enzyme D-aminoacid 
oxidase (DAO) is also able to generate free radicals when 
converting D-aminoacids in their corresponding cetoacids. 
Our principal aim is to increase radiotherapy effects, using 
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the combination of radiotherapy and DAO, in primary cultures 
from glioblastoma. 
 
Material and Methods: We have used primary cultures and 
stablished cell lines from patients with glioblastoma. 
Recombinant DAO carrying the C-terminal domain of the 
major lytic amidase (CLytA) specific for binding to choline 
was inmobilized to magnetic nanoparticles having a 
magnetite core covered with Diethylaminoethyl (DEAE) 
cellulose. Primary cultures were irradiated at 7 and 15 Gy. 
After irradiation, cultures were treated in the absence or in 
the presence of DAO (free or inmovilized in nanoparticles) 
and D-alanine (enzyme substrate). After irradiation, cells 
were harvested and cell cycle distribution was determined by 
flow citometry. 
 
Results: We have demonstrated in primary cultures from 
glioblastoma, that the treatment with DAO after irradiation, 
potentiates dramatically the effect of the radiation alone, 
increasing especially the percentage of cells in the sub-G1 
phase, an indicator of cell death. Some representative results 
are included in the attached file. DAO inmovilized in 
magnetic nanoparticles is more effective than free enzyme, 
since DAO is more stable at 37ºC inmovilized in nanoparticles.  
 
Conclusion: The combination of radiotherapy and enzymatic 
therapy with DAO based on the nanotechnology, induce an 
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Purpose or Objective: There are several indications that the 
Hedgehog (Hh) pathway could be a potential target for 
radiosensitization. Furthermore, a link between Hh signaling 
and the cellular energy metabolism has been described 
recently, more specific at the level of AMP-activated protein 
kinase (AMPK). Activation of AMPK, in turn, has also been 
shown to result in radiosensitization. Therefore, it seems 
worthwhile to explore whether the combination of Hh 
signaling inhibitors and AMPK activators such as metformin 
could further increase the response to radiotherapy. This 
combination strategy is being tested in prostate cancer (PCa) 
cells, as there is increasing evidence that the Hh pathway 
plays an important role in the development as well as 
progression to more advanced disease stages of PCa. 
 
Material and Methods: Three PCa cell lines (PC3, DU145, 
22Rv1) were treated for 72h with the SMO inhibitor GDC-0449 
(1µM, 10µM) or GLI1/2 inhibitor GANT61 (1µM, 10µM), with or 
without metformin (5mM). The effects on cell survival, 
proliferation and radiation sensitivity were investigated by 
means of Sulforhodamine B (SRB) assays, Bromodeoxyuridine 
(BrdU) assays and colony assays. The effects on gene and 
protein expression (qRT-PCR/Western blotting), cell cycle 
distribution (flow cytometry, PI staining) and DNA repair 
(flow cytometry, γH2AX) were also examined, both in the 
absence and presence of ionizing radiation (4Gy). 
 
Results: GDC-0449 on its own did not significantly affect cell 
proliferation, survival or radiation sensitivity of any of the 
PCa cell lines tested. Treatment with 10µM GANT61 on the 
other hand did result in a significant reduction of cell survival 
in all cell lines and induced radiosensitization in the 22Rv1 
cells (DEF(SF0.5)=1.39±0.11, p=0.002) (Fig 1A). The latter 
could be ascribed to the drug’s effect on apoptosis (Fig1B). 
Similar results as for GANT61 were observed after metformin 
monotherapy (DEF(SF0.5)=1.36±0.08, p=0.012). Moreover, 
metformin induced a significant downregulation of GLI1, both 
at the gene and protein expression level. While the 
combination of metformin and GDC-0449 resulted in no 
additional effects, addition of metformin to GANT61 further 
enhanced the radiosensitization effects as induced by single 




Conclusion: The GLI1/2 inhibitor GANT61 as well as 
metformin induced radiosensitization in the 22Rv1 PCa cells. 
The combination of both agents further enhanced the 
response to radiotherapy, indicating that this might be a 
more powerful radiosensitization strategy as compared to 
either agent alone. Investigations are currently ongoing to 
explore the underlying working mechanisms. 
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Purpose or Objective: The checkpoint kinases ATR and CHK1 
are considered promising targets for cancer treatment due to 
their roles in regulation of the S and G2 checkpoints and in 
the repair of DNA double strand breaks through homologous 
recombination. Interestingly, severe levels of hypoxia (<0.1% 
O2) have been shown to activate ATR/CHK1 signaling, which 
could likely make hypoxic cancer cells sensitive to inhibitors 
of these kinases. The aim of this project is to explore 
whether inhibition of ATR or CHK1 could be used to 
selectively target hypoxic cancer cells, both in combination 
with ionizing radiation and on its own. 
 
Material and Methods: Cancer cell lines U2OS, HCT116, 
H460, A549 and H1975 were treated with inhibitors of ATR 
(VE821, VE822) or Chk1 (AZD7762, UCN01) in the absence and 
presence of hypoxia (InVivo2 hypoxia chamber) and X-ray-
irradiation. Cells were analyzed by flow cytometry, 
immunoblotting and clonogenic survival assays. 
 
Results: We previously measured clonogenic survival, cell 
cycle distribution and activation of DNA damage signaling 
pathways in U2OS and HCT116 cancer cells at different 
oxygen concentrations (21%, 0.2% and 0.0% O2) in 
combination with the CHK1 inhibitors UCN-01 and AZD7762 
and ionizing radiation. We found that hypoxia alone did not 
alter the sensitivity to CHK1 inhibitors, but inhibition of CHK1 
after reoxygenation following periods of extreme hypoxia 
(0.0% O2) did result in decreased clonogenic survival and an 
increased fraction of γ-H2AX positive cells. Hypoxic cells 
were also found to be radiosensitized at least to the same 
extent as normoxic cells by CHK1 inhibition. Currently we are 
performing similar studies in lung cancer cell lines H460, 
A549 and H1975 treated with the ATR inhibitors VE821 and 
VE822. We have found that the number of γ-H2AX positive 
cells after ATR inhibition was higher in cells incubated at 
hypoxia (0.0% O2, 20h) compared to normoxia (21% O2). The 
ATR inhibitors also abrogated the radiation-induced G2 
checkpoint. Clonogenic survival assays are ongoing. 
 
Conclusion: These studies help determine the potential of 
using inhibitors of ATR and CHK1 to eradicate radioresistant 
hypoxic cancer cells 
 
 
